GenusPlus is flying under the radar here.
- FY22 - $295M revenues locked in & a tender pipeline of $344M in FY22. Management have stated they expect FY22 revenues to be circa $400M which equates to receiving around 1/3 of the FY22 pipeline. This may be under or over but management appear to be quite conservative.
- Revenues have grown YOY with a CAGR of 127% from FY18-FY21. Current valuation lets me buy this growth in revs for 0.5x
3. Net Income has also grown YOY in-line with revenues at a CAGR of 128% even with some slight dilution. Current valuation lets me buy this growth for 12x
4. SG&A margins have been declining approx. 4.3% YOY which is great to see also.5. Return ratios have also been very impressive with ROE averaging 28.5% & ROIC averaging 18.4%
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.01 |
Change
0.160(4.16%) |
Mkt cap ! $722.5M | |||
| Open | High | Low | Value | Volume |
| $4.04 | $4.08 | $3.93 | $1.352M | 336.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2817 | $4.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.01 | 912 | 1 |
View Market Depth
| Last trade - 16.10pm 30/06/2025 (20 minute delay) ? |
| GNP (ASX) Chart |